Advertisement

Topics

Companies Related to "Mangafodipir as an Adjunct to Percutaneous Coronary Intervention" [Most Relevant Company Matches] RSS

16:23 EST 16th February 2019 | BioPortfolio

Here are the most relevant search results for "Mangafodipir as an Adjunct to Percutaneous Coronary Intervention" found in our extensive corporate database of over 50,000 company records.

Showing "Mangafodipir Adjunct Percutaneous Coronary Intervention" Companies 1–25 of 268

Extremely Relevant

Ischemix

Ischemix is a privately-held drug discovery company with a portfolio of small molecule therapeutic compounds. The first of these compounds is targeted to reduce cell death and organ damage due to initial interruption and subsequent resumption of blood flow associated with cardiac surgeries and interventional procedures such as percutaneous coronary interve...


Relevant

Corindus Vascular Robotics

Corindus designs, manufactures and commercializes precision vascular robotic systems for use in minimally invasive procedures. The Company’s disposable medical device business model is enabled by a simple and low-cost console. The Company’s initial product, the CorPath™ system, is the world’s first to precisely drive coronary guidewires...

Kensey Nash

IntraLuminal Therapeutics, Inc. is a medical device company focused on both providing and developing products for the Interventional Cardiologist and Radiologist to cross and recanalize totally occluded arteries. The company was co-founded by Dr. Geoffrey Hartzler, pioneer of multi-vessel percutaneous transluminal coronary intervention (PTCI) and a recognized leader in the area of interventional c...


PlaqueTec Ltd.

PlaqueTec offers a first-of-its-kind catheter technology for cardiologists to routinely assess inflammation in the coronary artery, and better understand residual inflammatory risk. It has been proven to detect inflammatory molecules across the site of coronary artery disease (CAD), and can discriminate between patients with greater and lesser levels of co...

Corindus Vascular Robotics, Inc.

Corindus Vascular Robotics, Inc. (OTCQB: CVRS) is a global technology leader in robotic-assisted percutaneous coronary interventions (PCIs). The Company’s FDA-cleared CorPath 200 System is the first medical device that offers interventional cardiologists PCI procedure control from an interventional cockpit. With the CorPath System, Corindus Vascular R...

Rcadia Medical Imaging Ltd.

Rcadia Medical Imaging develops and markets automated image processing software products for blood vessel analysis in patients with suspected cardiovascular disease. The company's first FDA-cleared product, the COR Analyzer® System, provides fully automated analysis of Coronary CT angiography to enable the practical application of cCTA in detecting severe coronary artery disease. The COR Analyzer...

MacroChem

MacroChem (OTCBB: MACM.OB) is a specialty pharmaceutical company that develops and seeks to commercialize pharmaceutical products. Currently, our portfolio of product candidates is based on our proprietary drug delivery technologies: SEPA®, MacroDerm™ and DermaPass™. Our patented SEPA topical drug delivery technology (SEPA is an acronym for "Soft Enhancement of Percutaneous Absorption," where...

Rcadia Medical Imaging

Rcadia Medical Imaging develops and markets automated image processing software products for blood vessel analysis in patients with suspected cardiovascular disease. The company's first FDA-cleared product, the COR Analyzer® System, provides fully automated, real-time analysis of Coronary CT angiography to enable the practical application of cCTA in detecting severe coronary artery disease. The C...

Rcadia Medical Imaging, Ltd.

Rcadia Medical Imaging develops and markets automated image processing software products for blood vessel analysis in patients with suspected cardiovascular disease. The company's first FDA-cleared product, the COR Analyzer® System, provides fully automated, real-time analysis of Coronary CT angiography to enable the practical application of cCTA in detecting severe coronary artery disease. The C...

Percutaneous Systems, Inc.

Percutaneous Valve Technologies, Inc. (PVT)

Nil

Spectranetics

Spectranetics manufactures and sells the only excimer laser approved in the United States, Europe and Japan for use in multiple, minimally invasive cardiovascular procedures. This technology treats complex cardiovascular conditions by vaporizing lipid-based, calcified and fibrotic plaque, saphenous vein graft disease, and neointimal hyperplasia. Excimer laser is also used to remove scar tissue ho...

Bio-Intervention Specialists

Bio-IS does not replace the environmental services staff. Instead, Bio-IS works with hospital leadership, infection control committees and environmental services to implement a next-generation bio-intervention process. When new infection situations arise, Bio-IS can quickly attack such situations before they become worse.

InfraReDx, Inc.

InfraReDx, Inc., headquartered in Burlington, Massachusetts, is a privately-funded medical device company founded in 1998 and focused on intravascular characterization of disease in the coronary arteries. InfraReDx is the maker of the LipiScan(TM) system, a novel near-infrared (NIR) spectroscopy catheter that can detect the lipid core coronary plaques suspected to cause most heart attacks and know...

Cappella Medical Devices Ltd

Cappella, Inc. is a medical device company that develops novel solutions for the treatment of complex coronary artery disease (CAD) focused on protecting the coronary sidebranch arteries. Cappella’s Sideguard® coronary sidebranch technology offers interventional cardiologists a straightforward, effective, and easy to use solution that preserves the ...

Cappella, Inc.

Cappella, Inc. is a medical device company, developing novel solutions for the treatment of complex Coronary Artery Disease (CAD), specifically bifurcation disease. Cappella’s initial product, the Sideguard® Coronary Sidebranch Stent & Delivery System offers interventional cardiologists a straightforward, effective solution that focuses on treating...

Cappella Inc.

Cappella, Inc. is a medical device company, developing novel solutions for the treatment of complex Coronary Artery Disease (CAD) and specifically bifurcation vascular disease. Cappella's initial product, the Sideguard® Coronary Sidebranch Stent & Delivery System offers interventional cardiologists a straightforward, effective solution that focuses on treating the sidebranch of diseased coronary ...

Viz.ai

Viz.ai is a Direct-to-Intervention healthcare company that uses artificial intelligence and deep learning algorithms to analyze medical data and improve medical workflow. Direct-to-Intervention care leverages AI to communicate information about treatable patients straight to a specialist. We remove much of the friction in today’s stroke workflow by ...

EPIX Medical Incorporated

Based on its core, proprietary technology, EPIX is advancing its pipeline of products such as MS-325, the Company's lead MRI contrast agent currently in Phase III trials. MS-325 is also in development to help diagnose coronary artery disease, breast cancer, female sexual arousal dysfunction, atherosclerosis and myocardial perfusion. In addition to MS-325, EPIX's pipeline includes a new class of MR...

Atrium Medical Corporation

Atrium's vast expertise in medical device technologies for the treatment of coronary and vascular disease, chest trauma, hernia and soft tissue injury has brought a number of breakthrough advances in several diversified healthcare markets including interventional cardiology and radiology, chest trauma care and thoracic drainage, vascular surgery, and general surgery. Maintaining a commitment to th...

Osprey Medical, Inc.

Osprey Medical is a privately held company located in Eden Prairie, Minnesota. The Company is dedicated to the treatment and prevention of ailments originating from the inter-related functioning of the heart and kidneys with a primary focus on CIN. The Company’s CINCOR™ Contrast Removal System is a catheter based system that is designed to remove ...

Cappella Medical Devices Limited

Cappella, Inc. develops novel solutions for the treatment of complex coronary artery disease (CAD) - specifically bifurcation disease. Cappella’s Sideguard® coronary sidebranch technology offers interventional cardiologists a straightforward, effective, solution that focuses on treating the sidebranch of diseased coronary arteries first, rather tha...

Neural Intervention Technologies, Inc.

Neural Intervention Technologies (NIT) is a development stage medical device company focused on improving the quality of life of patients with blood vessel defects, including those of the brain that result in hemorrhagic stroke.NIT is developing ALGEL™-I and -II, novel embolic materials, into minimally invasive treatments for cerebral arteriovenous malformations and aneurysms. In addition, NIT w...

Racing Ahead

Racing Ahead is a leading provider of assessment and early intervention services for infants and toddlers at risk for developmental delays. Racing Ahead's staff serves as a knowledgeable resource for expert advice, information, intervention, and support for both parents and physicians. Racing Ahead also provides parent workshops and individualized instruction for infants and toddlers to accelera...

PLC Systems

PLC is a global leader in the development of products for performing a revolutionary new surgical procedure known as transmyocardial revascularization (TMR). TMR offers a completely new medical treatment option for patients who suffer from severe coronary artery disease. Coronary artery disease is the leading cause of death in the United States. Working with leading researchers and premier heart...


More From BioPortfolio on "Mangafodipir as an Adjunct to Percutaneous Coronary Intervention"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks